scholarly journals SURGICAL EMBOLECTOMY FOR ACUTE PULMONARY EMBOLISM: A MULTICENTER ANALYSIS OF OVER 58,000 CASES

2019 ◽  
Vol 35 (10) ◽  
pp. S126-S127
Author(s):  
E. Percy ◽  
R. Shah ◽  
S. Hirji ◽  
F. Yazdchi ◽  
T. Kaneko ◽  
...  
2021 ◽  
Author(s):  
B. Panholzer ◽  
H. Gravert ◽  
K. Huenges ◽  
A. Haneya ◽  
J. Cremer ◽  
...  

2016 ◽  
Vol 67 (13) ◽  
pp. 2054
Author(s):  
Timothy Lee ◽  
Shinobu Itagaki ◽  
Karan Omidvari ◽  
Joanna Chikwe ◽  
Natalia Egorova

2020 ◽  
Vol 110 (5) ◽  
pp. e403-e404 ◽  
Author(s):  
Andrea Audo ◽  
Valeria Bonato ◽  
Corrado Cavozza ◽  
Giulia Maj ◽  
Gianfranco Pistis ◽  
...  

2018 ◽  
Vol 38 (02) ◽  
pp. 98-105 ◽  
Author(s):  
Rolf Engelberger ◽  
Nils Kucher

AbstractDue to the manifold treatment options for the management of acute pulmonary embolism, state-of-the-art management requires risk stratification for choosing the adapted treatment for each patient. Reperfusion therapy is an integral part of therapy for patients with pulmonary embolism at high risk for mortality, but its role in patients with intermediate risk pulmonary embolism is more debated. The largest amount of evidence exists for systemic thrombolysis, which is an efficient therapy, but at the prize of an increased bleeding risk. In recent years, various types of catheter-based reperfusion therapies have been introduced, and evidence is growing that this therapy is as efficient as systemic thrombolysis, but with a more favourable safety profile. Surgical embolectomy remains a good alternative for unstable patients, especially for those with absolute contraindications for thrombolysis or after failed systemic thrombolysis. While the early benefits of reperfusion therapy are well documented, evidence for long-term benefit is still scarce. The scope of this review is to summarize the evidence for the currently available reperfusion therapies in the management of acute pulmonary embolism.


2021 ◽  
Vol 104 (8) ◽  
pp. 1376-1380

Acute pulmonary embolism (PE) is a life-threatening condition. In patient who has contraindication for systemic thrombolysis and inappropriate for surgical embolectomy, there is a role of catheter interventions. However, the data are limited. The aim of the present report was to assess a role of intrapulmonary artery thrombolysis bolus in acute PE. A retrospective review of the use of intrapulmonary artery thrombolysis in acute PE. The data were collected from 14 patients with massive or submassive PE who had contraindication or inappropriate for systemic thrombolysis and unsuitable for surgical embolectomy. After intrapulmonary thrombolysis was given, patients were followed clinically and hemodynamically until discharged and after 1 month. Pulmonary pressure was collected at pre and post intervention. Of the 14 patients (age 59±19 years, 78.6% female), 86% were diagnosed as submassive PE. Mean dose of tissue plasminogen activator (rt-PA) was 28±14 mg given as bolus and continuous infusion (19±10 hours). One patient died after completion of intrapulmonary infusion rt-PA at day 90, which did not relate to PE and the treatment. After intervention, mean PA pressure was significantly reduced from 32.3±6.0 to 21.0±4.3 mmHg (p<0.001). Three patients (21%) had minor bleeding (hematoma at access site). The present case series showed that intrapulmonary infusion of rt-PA was effective and safe in patient with massive and submassive PE who had contraindication or inappropriate to systemic thrombolysis or inoperable surgical thrombectomy. Keywords: Acute pulmonary embolism; Intrapulmonary thrombolysis; Tissue plasminogen activator; Surgical thrombectomy


2005 ◽  
Vol 10 (2) ◽  
pp. 85-89 ◽  
Author(s):  
Florian Kipfmueller ◽  
Rene Quiroz ◽  
Samuel Z Goldhaber ◽  
U Joseph Schoepf ◽  
Philip Costello ◽  
...  

Author(s):  
Per Lehnert ◽  
Christian H. Møller ◽  
Jann Mortensen ◽  
Jesper Kjaergaard ◽  
Peter Skov Olsen ◽  
...  

2020 ◽  
Author(s):  
Wang QiMin ◽  
Chen Liangwan ◽  
Chen Daozhong ◽  
Qiu Hanfan ◽  
Huang Zhongyao ◽  
...  

Abstract Backgroud: Acute pulmonary embolism (PE) is one of the most critical cardiovascular disease. The treatment for PE depends on the severity of disease including anticoagulation, systemic thrombolysis, surgical embolectomy,and catheter embolectomy. The indication of surgical pulmonary embolectomy is still controvery. Although there have been more favourable reports of the of surgical embolectomy (SE) over past decades, SE has still been used as a resort or rescue treatment for acute massive PE with significant hemodynamically unstable or present with cardiogenic shock or patients whose thrombolysis failed,therefore the high mortality of pulmonary surgical embolectomy was still reported. SE has not yet been accepted broadly as initial therapy in the algorithm for massive and submassive PE.Objective : The purpose of this study is to evaluate the early and midterm outcome of surgical pulmonary embolectomy which was taken as the first line therapy for acute central major pulmonary embolism in one single center in ChinaMethods: A retrospective review of patients who underwent surgical pulmonary embolectomy for acute pulmonary embolectomy was conducted from July of 2005 to Sept of 2019 at a single heart center in China. Patients with chronic thrombus or thrombendrterectomy were excluded.The risk factors for morbidity and mortality of the surgical pulmonary embolectomy were reviewed, The institutional echocardiographic database was searched for follow-up studies to compare markers of right ventricular function.Results: A total of 41 patients were included for the study, 17 cases (41.5%) had submassive PE and 24 (58.5%) had massive pulmonary embolism required preoperative positive inotropic treatment. Mean cardiopulmonary bypass time was 103.2±48.9 minutes, and 10 patients (24.4.%) underwent procedures without aortic cross-clamping. Ventilatory support time was 80.6±21.3hours. ICU stay was 4.51±3.23 days. Hospital stay was 12.8±6.4days. There was operative mortality 3 (7.32%) for massive pulmonary embolism and no death case of submassive pulmonary embolism. For massive PE patients, if the first choice treatment was surgical embolectomy, the mortality was low,only 2.56%, even though there were 2 cases suffered from cardiac arrest preoperatively. However, if 2 cases who received systemic thromblysis firstly were included in the datus,the mortality rate of SE increased to 12.5%. All cases had echocardiography results available for follow-up at discharge,and 30 cases at three months, only 10 cases at one years after surgical embolectomy. There were no death event related with recurrent PE in the follow-up,but 3 patents died of cerebral incranal bleeding, gastric cancer and gastric cancer at 1 year,3 years and 8 years after surgical embolectomy respectively.Conclusions: In this small retrospective single center experience, SE presented with low mortality rate when it was rendered as the first line treatment in selected patients for massive and submassive acute pulmonary embolism. SE should play the the same role as ST in the treatment algorithm for acute PE. Echocardiographic showed right ventricular function was improved in the early and midterm follow- up term


2004 ◽  
Vol 43 (5) ◽  
pp. A501
Author(s):  
Nicolas Meneveau ◽  
Luc Lorgis ◽  
Pierre Legalery ◽  
Marie-France Seronde ◽  
Florent Briand ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document